Mystery suitor spurs spike in CeNeS stock

Shares of UK biotech CeNeS Pharmaceuticals rocketed up almost 70 percent after the developer confirmed that it's engaged in talks with a mystery suitor. CeNeS had little to offer to enlighten investors, though, playing its cards close to its vest. Analysts were quick to look to CeNeS' lead product--the painkiller M6G--for a clue to who might be interested in acquiring the company.

One possible buyer is chairman Alan Goodman, who runs Avlar Bioventures. CeNeS shares have been weak, spurring some analysts to speculate it could be just as easy to buy the company as in-license M6G. Big in the pain field: Purdue Pharma, Abbott Laboratories and Boehringer Ingelheim.

- read the report from Dow Jones

Related Article:
CeNeS licenses promising sedative to Ono. Report
Dealmaking stays big even as the markets tremble. Report 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.